This post hoc analysis of an RCT compared long-term progression-free survival (PFS) between Retzius-sparing (RS) and standard anterior robot-assisted radical prostatectomy (RARP) in 120 men (aged 40–75) with low- to intermediate-risk prostate cancer, with a median follow-up of 77 months.
At 5 years, PFS was 80.2% in the RS group vs 91.1% in the anterior group (p = 0.01); after adjusting for CAPRA-S score, RS RARP was associated with a 2.64-fold higher likelihood of progression (p = 0.049).
- The original RCT was powered for early continence, **not** long-term oncological outcomes, limiting the validity of this analysis as a definitive oncological comparison. - Surgeons had limited prior experience with the RS approach, which may have inflated complication or margin rates. - Small sample size (n = 120) reduces statistical precision.
While RS RARP offers faster early continence recovery, clinicians should counsel patients that this approach was associated with significantly worse 5-year PFS in this trial, possibly due to surgeon learning-curve effects. Larger, oncologically-powered RCTs are needed before adopting RS RARP as a standard oncological approach.
Explore related topics